Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis
NCT03958851 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2019-05-24
Summary
All patients with SLE that will be admitted in internal medicine department from August 2019 to January 2021 are eligible to be targeted and included in the study. The diagnosis of SLE will be according to the 1997 American college of Romatology revised criteria (Hochberg 1997). SLE patients with lupus nephritis will take kidney biopsy for standard care of management according to American college of Romatology guidelines 2012. The study will include three groups as follow:
1 - SLE patients with lupus nephritis. 2- SLE patients without lupus nephritis 3-A group of age and sex matched healthy individuals. The first group will represent the study group while the second and third groups group will be taken as control group Exclusion criteria: patients with
1- Chronic renal failure 2- Diabetes mellitus (DM) 3-Obstructive nephropathy 4- Renal artery stenosis 5- Hypertension 6- Heart failure 7- Hepatic diseases. 8- Existing intra renal A-V fistula. 9-Renal vein thrombosis
Aims of the Research :
1. Assessment of the renal resistive index in patients with lupus nephritis (LN), in SLE patients without lupus nephritis and in the healthy controls.
2. Comparing the renal resistive index values in SLE patients with lupus nephritis with the SLE patients without LN and healthy controls.
3. Assessment of the correlation between renal resistive index (RRI) and histological findings in renal biopsy in patients with lupus nephritis.
4. Assessment of the correlation between renal resistive index (RRI) and renal function parameters (BUN, S Cr and eGFR).
5. Evaluation of the role of RRI as predictor of treatment outcomes in patients with lupus nephritis.
The study will be enrolled in three steps:
The first step:comparison of renal artery resistive index(RRI) values between study group and controls.
The second step :correlation between RRI of the patients with lupus nephritis and histological findings in renal biopsy and/ or kidney function parameters (BUN ,SCr , eGFR).
The third step:the patients with lupus nephritis will be followed up for six month receiving the usual treatment according to KDIGO guidelines 2012 to demonstrate the response to treatment in patient with pathological RRI compared to with normal RRI
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Doppler ultrasonography of renal arteries
Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as : RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken.
- DIAGNOSTIC_TEST
-
Renal biopsy
Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
- DIAGNOSTIC_TEST
-
kidney function tests
blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
- DIAGNOSTIC_TEST
-
The 24-hour urine protein test
The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
- DIAGNOSTIC_TEST
-
complete blood counting (CBC)
A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Ashraf A Elshazly, professor · Assiut University
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-08-01
- Primary Completion
- 2021-07-01
- Completion
- 2022-01-31
More Related Trials
-
Prediction of Outcome of Lupus Nephritis
NCT02403115 ·Status: UNKNOWN
-
Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN)
NCT06288308 ·Status: NOT_YET_RECRUITING
-
Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity
NCT06757725 ·Status: COMPLETED ·Phase: NA
-
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
NCT03179046 ·Status: COMPLETED
-
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
NCT03164720 ·Status: UNKNOWN
-
Identifying New Therapeutic Targets for Lupus Treatment
NCT03921398 ·Status: COMPLETED
-
Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients
NCT06287125 ·Status: NOT_YET_RECRUITING
-
The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study
NCT05588830 ·Status: UNKNOWN
-
Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Renal Biopsy
NCT05358652 ·Status: UNKNOWN
-
Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital
NCT05120882 ·Status: UNKNOWN
-
The Relation of Albumin/Globulin Ratio and Platelet/Albumin Ratio to Lupus Nephritis
NCT07130448 ·Status: NOT_YET_RECRUITING
-
Urinary Congophilia As an Indicator of Activity of Lupus Nephritis
NCT06654024 ·Status: NOT_YET_RECRUITING
-
Predictors of Bone Mineral Density in Lupus Nephritis Activity
NCT06837558 ·Status: NOT_YET_RECRUITING
-
Dynamic Imaging of Variation in Lupus Nephritis
NCT03180021 ·Status: COMPLETED
-
Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques
NCT03687138 ·Status: COMPLETED
-
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis
NCT06872138 ·Status: COMPLETED
-
Gut Microbiota Dysbiosis in Lupus Nephritis
NCT06231303 ·Status: NOT_YET_RECRUITING
-
A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital
NCT06491602 ·Status: RECRUITING
-
the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients
NCT05964751 ·Status: UNKNOWN
-
TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis
NCT04218890 ·Status: UNKNOWN
-
Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients
NCT01470183 ·Status: COMPLETED
-
Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
NCT05443516 ·Status: RECRUITING
-
The 2019 EULAR/ACR Classification Criteria as Predictor of Organ Damage in Systemic Lupus Erythematosus Patients
NCT06313151 ·Status: RECRUITING
-
Urinary G3BP as a Novel Biomarker in Lupus Nephritis
NCT06520670 ·Status: NOT_YET_RECRUITING
-
Functional MRI in Lupus Nephritis
NCT01731054 ·Status: COMPLETED